MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
Zynex Operating Income 2011-2026 | ZYXI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.99 M | 10.8 M | 22.9 M | 22.4 M | 10.2 M | 11.1 M | 10.4 M | 8.94 M | 640 K | -2.48 M | -5.7 M | -7.6 M | 2.74 M | 3.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | -7.6 M | 6.67 M |
Quarterly Operating Income Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -44 M | -10.3 M | -13.1 M | - | 3.8 M | 2.23 M | 525 K | - | 5.48 M | 2.71 M | 284 K | - | 6.56 M | 4.36 M | 1.91 M | 11.6 M | 8.05 M | 3.81 M | -1.08 M | 2.3 M | 1.41 M | 4.08 M | 2.46 M | 3.73 M | 2.5 M | 2.58 M | 2.26 M | 2.88 M | 2.82 M | 2.72 M | 1.96 M | 3.59 M | 2.94 M | 1.93 M | 483 K | 518 K | 622 K | -150 K | -350 K | - | -226 K | -363 K | -772 K | - | 412 K | -5.42 M | -1.29 M | - | -1.07 M | -2.56 M | -362 K | - | 712 K | 932 K | 486 K | - | 1.1 M | 899 K | -139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | -44 M | 323 K |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
AxoGen
AXGN
|
-3.29 M | $ 31.65 | -5.55 % | $ 1.4 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 43.45 | 1.31 % | $ 1.34 B | USA |
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.76 | 1.99 % | $ 701 M |  Israel |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.92 | 12.33 % | $ 136 M | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 17.97 | -20.68 % | $ 2.57 B | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 322.91 | -0.16 % | $ 9.11 B | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 53.33 | -2.07 % | $ 7.95 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 95.53 | -2.13 % | $ 141 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.1 | 11.41 % | $ 153 M |  France |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 124.29 | -1.27 % | $ 216 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 13.09 | -3.61 % | $ 1.01 B | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.49 | 29.56 % | $ 24 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 28.66 | -0.49 % | $ 242 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.49 | 0.35 % | $ 1.15 B | Israel |
 |
Pulmonx Corporation
LUNG
|
-57.7 M | $ 2.0 | -2.21 % | $ 78.2 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 171.78 | -0.58 % | $ 12.9 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.88 | -0.46 % | $ 90.4 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 97.57 | -1.39 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 20.12 | 9.89 % | $ 464 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 15.66 | 4.96 % | $ 423 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.6 | 0.27 % | $ 122 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Myomo
MYO
|
-10.7 M | $ 0.99 | 0.29 % | $ 6.98 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 91.33 | -3.28 % | $ 12.4 B | USA |